Asenapine Pharmacokinetics and Tolerability in a Pediatric Population with a Psychotic Disorder: Influence of Dosing Regimen

Friday, October 26, 2012

Peter Dogterom, Ph.D., Early Stage Development/Product Value Enhancement, Merck Sharp & Dohme, Oss, Netherlands

Robert A. Riesenberg, MD, Atlanta Center for Medical Research, Atlanta, GA

Michael Lesem, MD, Claghorn-Lesem Research Clinic, Houston, TX

Rik de Greef, MSc, Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Merck & Co., Inc., Kenilworth, NJ

AndrÈ Miltenburg, PhD, Early Stage Development, Merck Sharp & Dohme, Oss, Netherlands

Ronald Landbloom, MD, Merck & Co., Inc., Whitehouse Station, NJ

Matthew D. Troyer, MD, Early Stage Development, Merck & Co., Inc., North Wales, PA